Research suggests that Mucuna pruriens may support mood through its influence on dopaminergic and broader neurochemical pathways, with its primary active constituent L-DOPA serving as a precursor to dopamine and potentially affecting serotonin, norepinephrine, oxidative stress, and inflammatory processes as well. The available evidence comes primarily from animal studies and review articles rather than human clinical trials, with one animal study demonstrating anxiolytic and antidepressant effects in an obesity model and multiple reviews synthesizing the plant's neuroprotective and neurological mechanisms. Studies indicate a consistently supportive directional trend across this body of literature, suggesting biological plausibility for mood-related effects. However, a key limitation acknowledged across these sources is the absence of robust human clinical trials, meaning findings cannot yet be extrapolated to confirmed therapeutic outcomes in people.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Mucuna pruriens, a Possible Treatment for Depressive Disorders. | Review | 2024 | Supports | 95 |
| Mucuna pruriens Administration Minimizes Neuroinflammation and Shows Anxiolyt... | Other | 2020 | Supports | 90 |
| Mucuna pruriens in Parkinson's and in some other diseases: recent advancement... | Review | 2020 | Supports | 65 |
| A Comprehensive Review of the Therapeutic Potential of Mucuna Pruriens. | Review | 2026 | Supports | 60 |